
SWITZERLAND – Consortium of investors raise CHF 17m for Vivendy
BioMedInvest AG I, LSP Life Sciences Partners and TVM Capital closed a CHF 17m series-A round for Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland. Vivendy is a pharmaceutical start-up company that is developing an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. It was founded in 2006 as a spin-off from Inotech Biotechnologies AG.
Latest News
Verdane scores 5x MOIC in partial exit of Inriver to THL
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
CVC to buy sports nutrition specialist The Quality Group
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
DBAG to target EUR 1.3bn-EUR 1.5bn for new buyout fund next year
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Alcedo heads for June final close for Fund V
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap